[Federal Register Volume 78, Number 235 (Friday, December 6, 2013)]
[Notices]
[Page 73553]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-29099]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of Cripto-1
Point of Care (POC) Tests and Kits for the Detection of Colon and
Rectal Cancer, Breast Cancer, and Lung Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
Part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive patent
license to practice the inventions embodied in the following U.S.
Patents and Patent Applications to Beacon Biomedical LLC (``Beacon'')
located in Scottsdale, AZ, USA.
Intellectual Property: U.S. Patent No.7,078,176 issued July 18,
2006 entitled ``Detection and Quantification of Cripto-1'' [HHS Ref.
No. E-290-2000/0-US-03] and foreign equivalents thereof.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use will be limited to the use of Licensed Patent Rights
to develop FDA approved and/or 510K cleared Point of Care (POC) tests
and kits for the purpose of disease state recognition, detection,
diagnosis, monitoring, association and risk-stratification of colon and
rectal cancer, breast cancer, and lung cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
January 6, 2014 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Eggerton Campbell, Ph.D. Licensing and Patenting Manager,
Cancer Branch, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 435-5282; Facsimile: (301) 435-4013; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Cripto-1 (CR1) is a member of the epidermal
growth factor (EGF)-related families of peptides and is involved in the
development and progression of various human carcinomas. In particular,
CR1 overexpression has been detected in 50-90% of carcinomas of the
colon, pancreas, stomach, gallbladder, breast, lung, endometrium and
cervix. Current methodologies of cancer detection, e.g.
immunohistochemistry, can be time consuming, inconvenient and
oftentimes, inaccurate, and therefore, a need exists for more
efficient, reliable and less time consuming methods of detection. The
invention relates to such a method of detection. This test could be
used to more effectively screen and perhaps stage cancers.
Additionally, should particular tumor cells, e.g. breast tumor cells,
express a sufficiently high level of CR1, it may be possible to use the
disclosed assay to detect and measure CR1 in human serum and/or plasma
and possibly other physiological fluids.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part
404.7. The prospective exclusive license may be granted unless within
thirty (30) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 2, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-29099 Filed 12-5-13; 8:45 am]
BILLING CODE 4140-01-P